title: Frequency and prognostic value of cardiac troponin I elevation after coronary stenting.
abstract: Mild myocardial injuries after coronary angioplasty are associated with adverse late outcomes. The incidence and prognostic value of this phenomenon when using cardiac troponin I (cTnI) after stent implantation is unknown. We studied cTnI and creatine kinase (CK) release in 109 patients after stenting. Clinical success was achieved in 103 patients (94%). In-hospital major adverse coronary events were: death in 1 patient, Q-wave myocardial infarction in 1 patient, and non-Q-wave myocardial infarction in 2 patients. Twenty-nine patients (27%) had postprocedural cTnI increase, 16 (15%) had CK elevation. No preprocedural variables predicted marker elevation. Marker release was related to the occurrence of in-lab complications (59% vs 29% [p = 0.004 for cTnI] and 69% vs 32% [p = 0.011 for CK]). In 34% no explanation was found for cTnI increase. Success was more frequent in patients without cTnI elevation (100% vs 86%, p <0.001). The negative predictive value of cTnI increase was 100% for in-hospital major adverse coronary events (MACE), whereas its positive predictive value was 14%. cTnI and CK concordant elevation was associated with more intra- and postprocedural adverse events. During a mean follow-up of 8+/-3 months, major adverse coronary events were: death in 2 patients, myocardial infarction in 2 patients, and repeat PTCA in 8 patients. cTnI elevation was not predictive of these late MACE. cTnI elevation is common after stenting, and is related to the occurrence of in-lab complications. Its isolated elevation is not a good predictor of MACE. Patients with concordant cTnI and CK elevation seem to be at higher risk of in-hospital MACE.
authors.affiliation: Department of Cardiology, Tenon Hospital, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Garbarz
authors.forename: B
authors.initials: B
authors.lastname: Iung
authors.forename: G
authors.initials: G
authors.lastname: Lefevre
authors.forename: Y
authors.initials: Y
authors.lastname: Makita
authors.forename: B
authors.initials: B
authors.lastname: Farah
authors.forename: P
authors.initials: P
authors.lastname: Michaud
authors.forename: H
authors.initials: H
authors.lastname: Graine
authors.forename: A
authors.initials: A
authors.lastname: Vahanian
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D003327:Coronary Disease / Q000097:blood / Q000401:mortality / Q000628:therapy*; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000175:diagnosis* / Q000401:mortality; D011237:Predictive Value of Tests; D011379:Prognosis; D015607:Stents; D015996:Survival Rate; D019210:Troponin I / Q000097:blood*
chemical_list: D007527:Isoenzymes; D019210:Troponin I; D003402:Creatine Kinase